— Update 17 November 2020

— Update 17 November 2020

Research: Healthcare

Quantum Genomics — An accelerated pace of partnership agreements

Quantum Genomics continues to sign partnership deals for firibastat in difficult-to-treat/treatment-resistant hypertension, including two in the month of October. One of the agreements is with Qilu Pharmaceutical for the Greater China region, Hong Kong and Macau while the other is with Xediton Pharmaceuticals for Canada. Quantum Genomics announced its first partnership, with Biolab Sanus covering Latin America, in December 2019 and one covering South East Asia, Australia and New Zealand with Orient Europharma (OEP) in September. We expect additional agreements to be announced in the coming months, potentially covering the US and EU markets.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free